ICAM1 and malignant colon neoplasm: In cellular immunotherapy, bispecific CAR-T cells targeting EpCAM and intercellular adhesion molecule 1 (ICAM-1) have demonstrated remarkable efficacy [160], while EpCAM-CAR-NK92 cells exhibit a synergistic therapeutic effect with regorafenib in colon cancer [161].